Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Docosapentaenoic acid has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Elongase 2 and elongase 5 extend EPA by two carbons to give n-3 DPA, which is the obligatory intermediate on the route from EPA to DHA. n-3 DPA also retroconverts to EPA through beta-oxidation, which means supplementing it raises circulating EPA as well. That two-way traffic is the defining feature of this fatty acid. It behaves as a reservoir that feeds both directions.
To reach DHA, n-3 DPA is elongated to a 24-carbon intermediate, desaturated, and then shortened by one beta-oxidation cycle in the peroxisome. That final step is the bottleneck in humans, which is why conversion beyond n-3 DPA is limited. Supplementing n-3 DPA raises DPA and EPA reliably and DHA far less. The order of the pathway explains the pattern.
Most fish oil labels quantify only EPA and DHA even though a few percent of the oil is n-3 DPA. On top of that, the EPA delivered is partly elongated to DPA in the body. Someone already taking a marine oil is getting more of this fatty acid than the label states. That is worth knowing before adding a separate DPA product.
n-3 DPA is present at low single-digit percentages in most fish oils and at higher proportions in some marine mammal oils. It arrives as part of the triglyceride mixture rather than as an isolated compound. Because it is not usually quantified, intake from this route is invisible on a label. Total marine omega-3 intake is the more meaningful number.
Alpha-linolenic acid is desaturated and elongated toward EPA and then n-3 DPA. Conversion efficiency in humans is low, in the low single digits for EPA and lower still beyond it, and it is further suppressed by high linoleic acid intake. Plant sources therefore raise n-3 DPA far less than marine sources do. This is why relying on flaxseed for long-chain omega-3 status generally does not work.
Delta-6 desaturase acts on both linoleic acid and alpha-linolenic acid, and the larger pool wins by mass action. A diet heavy in omega-6 oils therefore suppresses conversion along the omega-3 route where n-3 DPA sits. Lowering linoleic acid intake raises the efficiency of the same enzymes for the omega-3 substrate. The competition is enzymatic, not absorptive.
With five double bonds, n-3 DPA oxidises readily both in the container and in the body. Tocopherol interrupts the peroxyl radical chain that drives that oxidation. Marine oil products add tocopherol as standard for shelf stability. The same chemistry applies to the fatty acid once it is in the membrane.
Astaxanthin partitions into the membrane and quenches reactive oxygen species there, which limits peroxidation of long-chain polyunsaturated fatty acids. The pairing comes from krill oil's natural composition rather than from a trial testing the two together. The described benefit is oxidative stability, not any measured clinical outcome. Read it as formulation rationale.
Krill oil delivers a share of its omega-3 fatty acids esterified to phospholipids rather than triglycerides, which follows a somewhat different absorption route. n-3 DPA is present as a minor component in that mixture. Whether the phospholipid vehicle changes DPA incorporation specifically has not been established. The vehicle question and the fatty acid question are separate.
Long-chain omega-3 fatty acids are largely stored esterified at the sn-2 position of membrane phospholipids, and phosphatidylcholine is the most abundant of those. Phospholipid delivery formats exist for exactly this reason. This describes the transport and storage chemistry rather than a tested combination. The fatty acid ends up in the same place regardless of the vehicle it arrived in.
Nothing specific on file for Docosapentaenoic acid. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 2 we read for Docosapentaenoic acid. The full linked list is below.
2 sources behind our Docosapentaenoic acid verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.